- Conditions
- Cognitive Function 1, Social
- Interventions
- Social Cognition Assessment and Training
- Behavioral
- Lead sponsor
- The University of Texas at Dallas
- Other
- Eligibility
- 17 Years to 40 Years
- Enrollment
- 153 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2006 – 2018
- U.S. locations
- 1
- States / cities
- Dallas, Texas
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 75
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Bipolar Disorder, Schizophrenia
- Interventions
- Seroquel IR 300mg, Seroquel IR 25mg, Quetiapine Formulation A 300mg, Quetiapine Formulation B 300mg, Quetiapine Formulation 25mg
- Drug
- Lead sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
- Industry
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 58 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019
- U.S. locations
- 1
- States / cities
- Long Beach, California
- Conditions
- Schizophrenia
- Interventions
- APN1125, Placebo
- Drug
- Lead sponsor
- CoMentis
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 58 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2015
- U.S. locations
- 1
- States / cities
- Glendale, California
- Conditions
- SCHIZOPHRENIA 1 (Disorder), Nicotine Use
- Interventions
- iTBS to the DMN, cTBS to the DMN, Sham rTMS
- Device
- Lead sponsor
- Vanderbilt University Medical Center
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Schizophrenia, Schizoaffective Disorder, or Schizophreniform Disorder
- Interventions
- Lurasidone HCl
- Drug
- Lead sponsor
- Sumitomo Pharma America, Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009
- U.S. locations
- 2
- States / cities
- Glendale, California • Wichita, Kansas
- Conditions
- Schizophrenia, Major Depressive Disorder, Bipolar I Disorder
- Interventions
- Aripiprazole + IEM (Ingestible Event Marker)
- Drug
- Lead sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 49 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016
- U.S. locations
- 4
- States / cities
- Granada Hills, California • Rochester, New York • Durham, North Carolina + 1 more
- Conditions
- Schizophrenia
- Interventions
- ASP6981, Placebo
- Drug
- Lead sponsor
- Astellas Pharma Global Development, Inc.
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018
- U.S. locations
- 2
- States / cities
- Glendale, California • Austin, Texas
- Conditions
- Schizophrenia and Disorders With Psychotic Features, Tobacco Use Disorder, Schizophrenia
- Interventions
- Transdermal Nicotine Patch, 21 mg transdermal nicotine, placebo patch
- Drug
- Lead sponsor
- National Institute on Drug Abuse (NIDA)
- NIH
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 48 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2002 – 2005
- U.S. locations
- 2
- States / cities
- Providence, Rhode Island
- Conditions
- Schizophrenia
- Interventions
- Risperidone ISM® 100 mg
- Drug
- Lead sponsor
- Rovi Pharmaceuticals Laboratories
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 81 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 2
- States / cities
- Long Beach, California • Berlin, New Jersey
- Conditions
- Schizophrenia
- Interventions
- KarXT
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 116 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 8
- States / cities
- Los Alamitos, California • Hollywood, Florida • Miami Lakes, Florida + 5 more
- Conditions
- Schizophrenia, Schizoaffective Disorder, Bipolar 1 Disorder
- Interventions
- clozapine, risperidone
- Drug
- Lead sponsor
- University of Texas Southwestern Medical Center
- Other
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 524 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 5
- States / cities
- Hartford, Connecticut • Athens, Georgia • Chicago, Illinois + 2 more
- Conditions
- Schizophrenia
- Interventions
- MEM 3454, Placebo for MEM 3454
- Drug
- Lead sponsor
- Memory Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 1
- States / cities
- Denver, Colorado
- Conditions
- Schizophrenia
- Interventions
- active H-coil delivered rTMS
- Device
- Lead sponsor
- The University of Texas Health Science Center, Houston
- Other
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2030
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Clinical High Risk, Early Psychosis, First Episode Psychosis
- Interventions
- Not listed
- Lead sponsor
- Columbia University
- Other
- Eligibility
- 12 Years to 29 Years
- Enrollment
- 25,000 participants
- Timeline
- 2025 – 2028
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Cognitive Impairment, Schizophrenia
- Interventions
- Eltoprazine, Placebo
- Drug
- Lead sponsor
- Amarantus BioScience Holdings, Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 31 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2012
- U.S. locations
- 6
- States / cities
- Los Angeles, California • Chicago, Illinois • Catonsville, Maryland + 3 more
- Conditions
- Schizophrenia
- Interventions
- ASP4345, Matching Placebo
- Drug
- Lead sponsor
- Astellas Pharma Global Development, Inc.
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 1
- States / cities
- Glendale, California
- Conditions
- Schizophrenia, Schizoaffective Disorder
- Interventions
- Aripiprazole Lauroxil
- Drug
- Lead sponsor
- Alkermes, Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 47 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 6
- States / cities
- Cerritos, California • Lemon Grove, California • Oakland, California + 3 more
- Conditions
- Healthy
- Interventions
- ziprasidone, B16 Fasted, B16 Fed
- Drug
- Lead sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 11 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Cognition, Healthy Participants
- Interventions
- Modafinil
- Drug
- Lead sponsor
- University of Minnesota
- Other
- Eligibility
- 18 Years to 35 Years
- Enrollment
- 103 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2030
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Schizophrenia
- Interventions
- Brexpiprazole (OPC-34712)
- Drug
- Lead sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
- Industry
- Eligibility
- 13 Years to 17 Years
- Enrollment
- 43 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 10
- States / cities
- Little Rock, Arkansas • Culver City, California • Orange, California + 7 more
- Conditions
- Schizophrenia
- Interventions
- Lurasidone HCl
- Drug
- Lead sponsor
- Sumitomo Pharma America, Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008
- U.S. locations
- 1
- States / cities
- Culver City, California
- Conditions
- Schizophrenia
- Interventions
- CVL-231
- Drug
- Lead sponsor
- Cerevel Therapeutics, LLC
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 15 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2023
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Schizophrenia, Schizoaffective, Bipolar Disorder 1
- Interventions
- Yoga-based Exercise (YE), Wellness Lifestyle Program (WLP)
- Other
- Lead sponsor
- VA Office of Research and Development
- Federal
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 112 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Schizophrenia
- Interventions
- EN3342
- Drug
- Lead sponsor
- Endo USA Inc., a Keenova Therapeutics Company
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 1
- States / cities
- Marlton, New Jersey